Browse OR51E1

Summary
SymbolOR51E1
Nameolfactory receptor, family 51, subfamily E, member 1
Aliases OR51E1P; OR52A3P; GPR164; olfactory receptor, family 51, subfamily E, member 1 pseudogene; D-GPCR; DGPCR; GP ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein
Domain PF13853 Olfactory receptor
Function

Odorant receptor.

> Gene Ontology
 
Biological Process GO:0007608 sensory perception of smell
GO:0050907 detection of chemical stimulus involved in sensory perception
GO:0050911 detection of chemical stimulus involved in sensory perception of smell
Molecular Function GO:0004984 olfactory receptor activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04740 Olfactory transduction
Reactome R-HSA-388396: GPCR downstream signaling
R-HSA-381753: Olfactory Signaling Pathway
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolOR51E1
Nameolfactory receptor, family 51, subfamily E, member 1
Aliases OR51E1P; OR52A3P; GPR164; olfactory receptor, family 51, subfamily E, member 1 pseudogene; D-GPCR; DGPCR; GP ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between OR51E1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolOR51E1
Nameolfactory receptor, family 51, subfamily E, member 1
Aliases OR51E1P; OR52A3P; GPR164; olfactory receptor, family 51, subfamily E, member 1 pseudogene; D-GPCR; DGPCR; GP ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of OR51E1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolOR51E1
Nameolfactory receptor, family 51, subfamily E, member 1
Aliases OR51E1P; OR52A3P; GPR164; olfactory receptor, family 51, subfamily E, member 1 pseudogene; D-GPCR; DGPCR; GP ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of OR51E1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6440.0137
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.8880.0568
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4710.238
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0280.962
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1790.852
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.290.789
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3840.286
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.460.423
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3190.599
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4190.678
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3740.286
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0920.593
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of OR51E1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.42.74.70.294
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.43.440.587
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512200200.294
Summary
SymbolOR51E1
Nameolfactory receptor, family 51, subfamily E, member 1
Aliases OR51E1P; OR52A3P; GPR164; olfactory receptor, family 51, subfamily E, member 1 pseudogene; D-GPCR; DGPCR; GP ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of OR51E1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolOR51E1
Nameolfactory receptor, family 51, subfamily E, member 1
Aliases OR51E1P; OR52A3P; GPR164; olfactory receptor, family 51, subfamily E, member 1 pseudogene; D-GPCR; DGPCR; GP ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of OR51E1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by OR51E1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolOR51E1
Nameolfactory receptor, family 51, subfamily E, member 1
Aliases OR51E1P; OR52A3P; GPR164; olfactory receptor, family 51, subfamily E, member 1 pseudogene; D-GPCR; DGPCR; GP ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of OR51E1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolOR51E1
Nameolfactory receptor, family 51, subfamily E, member 1
Aliases OR51E1P; OR52A3P; GPR164; olfactory receptor, family 51, subfamily E, member 1 pseudogene; D-GPCR; DGPCR; GP ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of OR51E1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolOR51E1
Nameolfactory receptor, family 51, subfamily E, member 1
Aliases OR51E1P; OR52A3P; GPR164; olfactory receptor, family 51, subfamily E, member 1 pseudogene; D-GPCR; DGPCR; GP ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between OR51E1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolOR51E1
Nameolfactory receptor, family 51, subfamily E, member 1
Aliases OR51E1P; OR52A3P; GPR164; olfactory receptor, family 51, subfamily E, member 1 pseudogene; D-GPCR; DGPCR; GP ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting OR51E1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.